Iceni Glycoscience and the University of Warwick (UoW) have undertaken a synergistic collaboration on SARS-CoV2, in an attempt to develop a variant-proof, carbohydrate-based test to identify infected individuals. The collaboration started in the early phase of the pandemic (March 2020), with the first initial results published in The American Chemical Society (ACS) journal, showing the synergies between the polymer-based approach developed from UoW combined with the knowledge of Iceni Glycoscience, based on its human flu developments and adapted to the SARS-CoV2 . The follow up publication showed promising data on clinical samples and an ongoing development and internal validation programme has been established in collaboration with leading lateral flow developer, Mologic.
